

BIOLOGICS AND INTER PARTES REVIEWS (as of 6/20/2016)

Drug	Sales (2014)	Petitioner	Patent No.	Type of Claim	Status
CroFab	\$67.5m	Laboratories Silanes et al.	8,048,414	Composition	Terminated
		Bioactive Laboratories	8,048,414	Method	Denied
Enbrel	\$8.5b	Coalition for Affordable Drugs V LLC	8,163,522	Method/Composition	Denied
Humira	\$12.5b	Amgen Inc.	8,916,157	Formulation	Denied
			8,916,158	Formulation	Denied
		Coherus BioSciences Inc.	8,889,135	Method	Instituted
			9,017,680	Method	Instituted
			9,073,987	Method	Instituted
			9,114,166	Formulation	Pending
		Boehringer Ingelheim	8,889,135	Method	Pending
			8,889,135	Method	Pending
Kadcyla	\$555m	Phigenix, Inc.	8,337,856	Composition	Final Decision
			7,575,748	Method	Denied
Myozyme/ Lumizyme	\$610m	BioMarin Pharmaceutical Inc.	7,351,410	Method	Final Decision
			7,056,712	Method	Final Decision
			7,655,226	Method	Final Decision
Orencia	\$1.65b	Momenta Pharmaceuticals Inc.	8,476,239	Formulation	Instituted
Epogen/ Procrit	\$3.2b	Hospira, Inc.	6,747,002	Method	Terminated
Rituxan	\$8.7b	Boehringer Ingelheim	7,976,838	Method	Instituted
			7,820,161	Method	Instituted half of the challenged claims (1, 2, 5, 6, 9, and 10)
			8,329,172	Method	Denied
		Celltrion, Inc.	7,976,838	Method	Terminated
			7,820,161	Method	Terminated
Tysabri	\$2.0b	Swiss Pharma Int'l AG	8,815,236	Method	Pending
			8,349,321	Formulation	Pending
			8,900,577	Formulation	Pending
Total Sales	\$37.78b				